Man Group PLC Reata Pharmaceuticals Inc Transaction History

Man Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $230,979 - $434,231	11,900 Added 86.86%	25,600 $643,000
Q2 2022 Aug 15, 2022	BUY	$20.71 - $36.5 $283,727 - $500,050	13,700 New	13,700 $416,000
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $236,508 - $1.02 Million	-9,235 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $53,300 - $76,229	-533 Reduced 5.46%	9,235 $930,000
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $2.22 Million - $4.29 Million	-28,372 Reduced 74.39%	9,768 $1.38 Million
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $1.49 Million - $2.1 Million	15,785 Added 70.61%	38,140 $3.8 Million
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $2.28 Million - $4.13 Million	22,355 New	22,355 $2.76 Million
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $3.38 Million - $4.11 Million	-43,543 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$51.9 - $101.79 $1.39 Million - $2.72 Million	-26,757 Reduced 38.06%	43,543 $3.72 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $76.44 $3.43 Million - $5.37 Million	70,300 New	70,300 $3.94 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.